VOICED : China exhibe por primera vez sus vacunas contra el coronavirus

Chinese vaccines by Sinovac and Sinopharm were showcased at a Beijing trade fair, raising expectations. They are in Phase 3 trials, with hopes for year-end efficacy data and authorization. Sinovac has built a plant to produce 300 million doses annually. Initial vaccinations will target high-risk groups, with broader inoculation based on epidemic needs. China faces criticism for its COVID-19 response, but vaccine development may improve its image. More information is available at ISGlobal.org.

Which companies were involved in the production of the Chinese vaccines showcased in Beijing?

• Sinovac Biotech and Sinopharm

• Pfizer and Moderna

• Johnson & Johnson and AstraZeneca

• BioNTech and CureVac

What phase are the clinical trials of the Chinese vaccine currently in?

• Phase 3

• Phase 1

• Phase 2

• Phase 4

How many doses per year is Sinovac's new plant expected to produce?

• 200 million

• 400 million

• 100 million

• 300 million

Who will be prioritized for vaccination once the Chinese vaccine is available?

• All citizens immediately

• Tourists and travelers

• High-risk individuals and close contacts

• Children and teenagers

What criticism does China face from Western countries regarding its handling of the coronavirus outbreak?

• Excessive travel restrictions

• Lack of international cooperation

• Overproduction of vaccines

• Delayed response to the outbreak